(ACB) Aurora Cannabis - Ratings and Ratios
Cannabis, Cannabis-Derivative Products, Vegetables, Floral Plants
ACB EPS (Earnings per Share)
ACB Revenue
Description: ACB Aurora Cannabis
Aurora Cannabis Inc (NASDAQ:ACB) is a cannabis production and distribution company operating in Canada and internationally, offering medical and consumer cannabis products, as well as plant propagation services. The companys diverse portfolio includes well-known medical cannabis brands such as MedReleaf, CanniMed, and Aurora.
From a business perspective, Aurora Cannabis has a significant presence in the Canadian cannabis market and is expanding its reach globally. To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of revenue can be analyzed. For instance, Auroras revenue growth rate can be compared to industry averages to gauge its competitive position.
In terms of valuation, Aurora Cannabis has a market capitalization of $235.38M USD, with a price-to-earnings (P/E) ratio of 18.86, indicating that the stock may be relatively expensive compared to its earnings. However, the forward P/E ratio is significantly higher at 95.24, suggesting that the market expects substantial earnings growth in the future. Return on Equity (RoE) is 0.28, which is a relatively low value, indicating that the company may not be generating sufficient profits from its equity.
To further analyze Aurora Cannabis stock performance, technical indicators such as moving averages and average true range (ATR) can be used. Although the current stock price is below its 20-day and 50-day simple moving averages (SMA20 and SMA50), it is still above its 52-week low, indicating some level of support. A more detailed analysis of the stocks price action and volatility can provide insights into potential trading opportunities.
Additional Sources for ACB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
ACB Stock Overview
| Market Cap in USD | 253m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-07-11 |
ACB Stock Ratings
| Growth Rating | -86.8 |
| Fundamental | -4.43 |
| Dividend Rating | 0.0 |
| Rel. Strength | -19.2 |
| Analysts | 4.17 of 5 |
| Fair Price Momentum | 2.44 USD |
| Fair Price DCF | - |
ACB Dividends
Currently no dividends paidACB Growth Ratios
| Growth Correlation 3m | -3% |
| Growth Correlation 12m | -47.1% |
| Growth Correlation 5y | -91.1% |
| CAGR 5y | -48.09% |
| CAGR/Max DD 5y | -0.49 |
| Sharpe Ratio 12m | -1.22 |
| Alpha | -39.55 |
| Beta | 1.138 |
| Volatility | 68.64% |
| Current Volume | 692.9k |
| Average Volume 20d | 1328.2k |
| Stop Loss | 4.3 (-4.2%) |
As of July 16, 2025, the stock is trading at USD 4.49 with a total of 692,913 shares traded.
Over the past week, the price has changed by -1.54%, over one month by -26.99%, over three months by +6.15% and over the past year by -26.27%.
Neither. Based on ValueRay´s Fundamental Analyses, Aurora Cannabis is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -4.43 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACB is around 2.44 USD . This means that ACB is currently overvalued and has a potential downside of -45.66%.
Aurora Cannabis has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy ACB.
- Strong Buy: 3
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, ACB Aurora Cannabis will be worth about 2.8 in July 2026. The stock is currently trading at 4.49. This means that the stock has a potential downside of -37.42%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.1 | 614.3% |
| Analysts Target Price | 32.1 | 614.3% |
| ValueRay Target Price | 2.8 | -37.4% |